Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California START, Midwest, Grand Rapids, Michigan START, Astera, East Brunswick, New Jersey NEXT, Dallas, Irving, Texas START San Antonio, San Antonio, Texas START, Mountain Region, West Valley City, Utah NEXT, Virginia, Fairfax, Virginia